Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biotechnology Advances

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.biotechadv.2011.05.011PMID 21620943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS and BRAF: drug targets and predictive biomarkers

  2011cited by this paper
• Small molecule inhibition of protein depalmitoylation as a new approach towards downregulation of oncogenic Ras signalling.

  2011cited by this paper
• Binding properties and biological characterization of new sugar-derived Ras ligands

  2011cited by this paper
• Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

  2011cited by this paper
• Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

  2010cited by this paper
• Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth

  2010cited by this paper
• The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

  2010cited by this paper
• Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

  2010cited by this paper
• Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes.

  2010cited by this paper
• Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*

  2010cited by this paper
• Identification of RNA Aptamer Specific to Mutant KRAS Protein

  2010cited by this paper
• Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

  2010cited by this paper
• Salirasib in the treatment of pancreatic cancer.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Cell-penetrating peptides and their therapeutic applications

  2009cited by this paper
• First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.

  2009influential reference
• Recent advances in the use of cell-penetrating peptides for medical and biological applications.

  2009cited by this paper
• Fundamental link between folding states and functional states of proteins.

  2009influential reference
• Proepithelin is an autocrine growth factor for bladder cancer.

  2009cited by this paper
• The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

  2009cited by this paper
• Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

  2009influential reference
• p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling.

  2009cited by this paper
• [Targeting KRAS pathway in NSCLC therapy].

  2009cited by this paper
• Genetic and Pathogenetic Aspects of Noonan Syndrome and Related Disorders

  2009cited by this paper
• Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

  2009cited by this paper
• RAS in cellular transformation and senescence.

  2009cited by this paper
• Stratégies thérapeutiques ciblant la voie KRAS dans le cancer bronchique non à petites cellules

  2009cited by this paper
• Differences in flexibility underlie functional differences in the Ras activators son of sevenless and Ras guanine nucleotide releasing factor 1.

  2009cited by this paper
• Present treatment and future expectations in advanced pancreatic cancer.

  2008cited by this paper
• K-ras as a Target for Lung Cancer Therapy

  2008cited by this paper
• The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders

  2008cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• GEFs and GAPs: critical elements in the control of small G proteins.

  2007cited by this paper
• Glucose‐Derived Ras Pathway Inhibitors: Evidence of Ras–Ligand Binding and Ras–GEF (Cdc25) Interaction Inhibition

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Hedgehog/Ras interactions regulate early stages of pancreatic cancer.

  2006cited by this paper
• Tipifarnib: farnesyl transferase inhibition at a crossroads

  2006cited by this paper
• Ras-dependent carbon metabolism and transformation in mouse fibroblasts

  2006cited by this paper
• Discovery and characterization of inhibitors of human palmitoyl acyltransferases

  2006cited by this paper
• Characterization of interactions between ras family GTPases and their effectors.

  2006cited by this paper
• Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts.

  2006cited by this paper
• A Ras-induced conformational switch in the Ras activator Son of sevenless

  2006influential reference
• Lonafarnib in cancer therapy

  2006cited by this paper
• Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells

  2006cited by this paper
• Catalytic competence of the Ras–GEF domain of hSos1 requires intra‐REM domain interactions mediated by Phenylalanine 577

  2006influential reference
• Conformational states of Ras complexed with the GTP analogue GppNHp or GppCH2p: implications for the interaction with effector proteins.

  2005cited by this paper
• The isolated catalytic hairpin of the Ras‐specific guanine nucleotide exchange factor Cdc25Mm retains nucleotide dissociation activity but has impaired nucleotide exchange activity

  2005influential reference
• Signaling interplay in Ras superfamily function.

  2005cited by this paper
• Perturbation of the conformational equilibria in Ras by selective mutations as studied by 31P NMR spectroscopy

  2004cited by this paper
• Inducible Activation of Oncogenic K-ras Results in Tumor Formation in the Oral Cavity

  2004cited by this paper
• Delivery of bioactive molecules into the cell: the Trojan horse approach.

  2004cited by this paper
• Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

  2004cited by this paper
• The TAT Protein Transduction Domain Enhances the Neuroprotective Effect of Glial-Cell-Line-Derived Neurotrophic Factor after Optic Nerve Transection

  2004cited by this paper
• Ras redux: rethinking how and where Ras acts.

  2003cited by this paper
• GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila.

  2003cited by this paper
• Activation of the Ras superfamily of small GTPases

  2003cited by this paper
• Stable suppression of tumorigenicity by virus-mediated RNA interference.

  2002cited by this paper
• A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases.

  2002cited by this paper
• Solution structure of the Ras binding domain of the protein kinase Byr2 from Schizosaccharomyces pombe.

  2001cited by this paper
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• The Guanine Nucleotide-Binding Switch in Three Dimensions

  2001cited by this paper
• Dynamic properties of the Ras switch I region and its importance for binding to effectors

  2001cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Ras-A Molecular Switch Involved in Tumor Formation.

  2000cited by this paper
• A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts

  2000influential reference
• Thermodynamic and Kinetic Characterization of the Interaction between the Ras Binding Domain of AF6 and Members of the Ras Subfamily*

  1999cited by this paper
• Characterization and Properties of Dominant-negative Mutants of the Ras-specific Guanine Nucleotide Exchange Factor CDC25Mm *

  1999influential reference
• Essential role for oncogenic Ras in tumour maintenance

  1999cited by this paper
• Guanosine triphosphatase stimulation of oncogenic Ras mutants.

  1999cited by this paper
• The structural basis of the activation of Ras by Sos

  1998cited by this paper
• Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm.

  1998influential reference
• Ras farnesyltransferase: a new therapeutic target.

  1997cited by this paper
• Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

  1997cited by this paper
• Structure of the Ras-binding domain of RalGEF and implications for Ras binding and signalling

  1997cited by this paper
• Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP.

  1996cited by this paper
• Cell cycle-dependent activation of Ras.

  1996cited by this paper
• Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator.

  1992cited by this paper
• High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.

  1989cited by this paper
• ras gene Amplification and malignant transformation

  1985cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Solution

  1902cited by this paper

• FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization

  2025cites this paper
• Deubiquitinase OTUD7B Regulates Cell Proliferation in Breast Cancer.

  2024cites this paper
• Cannabidiol Antiproliferative Effect in Triple-Negative Breast Cancer MDA-MB-231 Cells Is Modulated by Its Physical State and by IGF-1

  2022cites this paper
• The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells

  2021cites this paper
• Asymmetric organocatalysis: an enabling technology for medicinal chemistry.

  2021cites this paper
• Biology, pathology, and therapeutic targeting of RAS.

  2020cites this paper
• Targeting der kleinen GTPasen über ihre regulatorischen Proteine

  2020cites this paper
• Structure identification, antitumor activity and mechanisms of a novel polysaccharide from Ramaria flaccida (Fr.) Quél

  2020cites this paper
• Targeting the Small GTPase Superfamily through Their Regulatory Proteins

  2020cites this paper
• Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

  2018cites this paper
• Integrated approach to study Ras-dependent cancer metabolic rewiring in mouse fibroblasts

  2017cites this paper
• Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).

  2017cites this paper
• K-Ras Activation Induces Differential Sensitivity to Sulfur Amino Acid Limitation and Deprivation and to Oxidative and Anti-Oxidative Stress in Mouse Fibroblasts

  2016cites this paper
• miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1

  2016cites this paper
• Targeting oncogenic signaling proteins : new insights using a FRET-based chemical biology approach

  2016influential citation
• Direct Modulation of Small GTPase Activity and Function.

  2015cites this paper
• Direkte Modulation von Aktivität und Funktion kleiner GTPasen

  2015cites this paper
• Small-molecule modulation of Ras signaling.

  2014cites this paper
• Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy

  2014cites this paper
• State 1(T) inhibitors of activated Ras.

  2013cites this paper
• The Current Status of Human Anti-Cancer Vaccines

  2013cites this paper
• Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present)

  2012cites this paper
• Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein.

  2012cites this paper
• Metall‐Bis(2‐picolyl)amin‐Komplexe als Zustand‐1(T)‐Inhibitoren für aktiviertes Ras‐Protein

  2012cites this paper
• Immunobiological properties of cancer stem cells isolated from colorectal cancer patients

  2012cites this paper